« Back to news

Evonetix, a spin out company from Cambridge Consultants Ltd, choose Chesterford Research Park as location from which to continue to grow

Evonetix, a spin out company from Cambridge Consultants Ltd, choose Chesterford Research Park as location from which to continue to grow


Start-up developing and commercialising a new approach to the synthesis of DNA has taken two suites in Science Village 

Chesterford Research Park is delighted to confirm that Evonetix has taken two suites within Science Village – an innovative, energy efficient building offering individual R&D suites from 1,515 sq ft to 1,993 sq ft.

Evonetix was founded in late 2015 with the support of Cambridge Consultants Ltd (CCL) and the entrepreneur and co-founder of Amadeus Capital Partners, Hermann Hauser.  The company is developing a novel method of manufacturing DNA molecules, using a microchip-based array. The resulting economies of scale mean that Evonetix’ technology will be more economical and flexible than the currently available methods, as well as being more comprehensive in its output. Given that DNA is the raw material for the fast-emerging and exciting field of synthetic biology, economical and flexible manufacture is critical.

Nick McCook, CEO, Evonetix commented of the move: “I am personally delighted to be back at Chesterford, having been CEO at Solexa; pioneers of next-generation sequencing and a previous occupier at the Park that eventually went on to become part of Illumina.  Our CSO, Joe Brennan, was also part of the Solexa team and we have enjoyed a long and successful association with Chesterford and one which we look forward to continuing as we develop Evonetix.”

The Evonetix team currently consists of 15 staff and continued growth will be based on the achievement of key milestones and the necessary funding to deliver them.

Chesterford Research Park’s low-density development, set within 250 acres of impressive parkland, offers not only ultra modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within The Nucleus building - which includes a restaurant, café bar, health and fitness centre and meeting and conferencing space. The Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies. Evonetix joins major players such as AstraZeneca, Illumina Inc and Domainex, who have also chosen Chesterford as the base from which to advance their research and development.

INVEST Essex, Essex County Council’s inward investment team, worked with Evonetix on their choice of site and introduced them to Uttlesford District Council who were able to provide support to Evonetix with their Business Development Rate Relief Scheme. INVEST Essex continue to work with Evonetix offering skills support.

For further information regarding occupancy options please contact the joint agents for Chesterford Research Park – William Clarke at Savills (01223) 347294 or Michael Jones at Dodson Jones (01223) 358114.


Share this: